Agency / Source: SCHOTT North America

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SCHOTT Pharma Launches Prefillable Syringes (PFS) for Deep-cold Drugs - First on the market: Safely storing deep-cold medications with prefillable polymer syringes -
SCHOTT Pharma Launches Prefillable Syringes (PFS) for Deep-cold Drugs


PRZOOM - /newswire/ - Mainz, Rhineland-Palatinate, Germany, 2023/05/17 - First on the market: Safely storing deep-cold medications with prefillable polymer syringes -

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


• SCHOTT Pharma’s prefillable polymer syringes are a trailblazing solution for drug applications that need to be stored and transported on dry ice at temperatures approaching -100°C.
• Top players in the field are in the process of commercial approval for mRNA applications in SCHOTT Pharma’s prefillable polymer syringes.
• Scientific data packages on the syringes’ performance at deep-cold temperatures support pharma companies in bringing their drugs to market.

SCHOTT Pharma, a pioneer in pharmaceutical drug containment solutions and delivery systems, launches prefillable syringes (PFS) for deep-cold drugs, which are stored and transported on dry ice at temperatures reaching -100°C. The PFS are made of an advanced pharmaceutical-grade polymer and are delivered to pharma companies in a standardized nest and tub configuration, thereby ensuring compatibility on major fill-and-finish lines to simplify the filling process. “While prefillable syringes are typically favored for drug delivery due to their speed and convenience, they were not a viable option for drugs that require storage at -100°C. But now, for the first time, deep-cold medications can be introduced to the market using prefillable polymer syringes,” said Andreas Reisse, CEO at SCHOTT Pharma. “The drug development pipeline for these drugs is extensive, including various therapies such as mRNA, cell, and gene therapies.” As part of the offering, drug manufacturers can benefit from an extensive scientific data package developed by SCHOTT Pharma that details the 1 ml long syringes’ performance at deep-cold temperatures. In addition, the PFS raise the bar on quality with a best-in-class specification as well as a fast-track supply process to ensure that drug manufacturers can achieve a fast time to market.

Deep-cold medications require innovative delivery systems that can withstand harsh conditions. SCHOTT Pharma’s polymer PFS were developed to protect these drugs even at temperatures approaching -100°C while maintaining syringe functionality, such as break loose and gliding force and container closure integrity. “Our polymer syringes are a favorable choice for deep-cold drugs thanks to the entire platform system, which includes the polymer material, siliconization, the plunger material, and the overall quality management system, among others,” explains Mario Haas, Head of Business Segment Drug Delivery Systems at SCHOTT Pharma. “Based on our track record in the field of mRNA-based applications, we are ready to bring the next deep-cold drugs to the market together with our customers.”
High-quality portfolio for deep-cold medications

Known as SCHOTT TOPPAC® freeze, the drug delivery system is made of cyclic olefin copolymer (COC). The material is break-resistant, biologically inert, and features advanced barrier properties to ensure drug stability. In addition, the scientific data package includes data on container closure integrity, functionality, and particulate generation after freeze and thaw cycles. “Furthermore, our state-of-the-art manufacturing process is designed to achieve consistently high quality. Combined with enhanced quality control of all critical to quality (CtQ) syringe attributes, we can ensure that each polymer syringe fulfills the high requirements needed for deep-cold applications,” adds Haas.

The polymer syringes are part of SCHOTT Pharma’s portfolio, which features solutions for all life cycle stages of deep-cold medications. Besides polymer syringes, the deep-cold portfolio includes vials for a quick launch and fast time-to-market as well as glass syringes.

About SCHOTT Pharma

SCHOTT Pharma ( designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world because human health matters. The portfolio comprises drug containment and delivery solutions for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 65 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house, a state-of-the-art R&D center in Switzerland, and around 130 employees in R&D, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA, headquartered in Mainz, Germany, is part of SCHOTT AG that is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated sales of EUR 821 million in the fiscal year 2022.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: SCHOTT North America


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker


Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

SCHOTT Pharma Launches Prefillable Syringes (PFS) for Deep-cold Drugs

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Contact: Rina Della Vecchia - SCHOTT North America, Inc. 
914-831-2286 rina.dellavecchia[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SCHOTT North America securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Press Releases From SCHOTT North America / Company Profile

Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

NEC Selected by AMED for Design of A Universal Vaccine that is Effective Against Influenza Virus Strains
BostonGene, NEC and JIP Form Joint Venture in Japan
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib
US FDA Approves Ipsen’s Sohonos™ (palovarotene) Capsules, the First and Only Treatment for People with Fibrodysplasia Ossificans Progressiva
SCHOTT Pharma Strengthens Leading Position in the First Year as Stand-alone Company
Frost & Sullivan Awarded Duopharma Biotech with the 2022 Malaysian Company of the Year Award
Duopharma Biotech Applauded by Frost & Sullivan for Providing Innovative Healthcare Solutions in the Malaysian Market
Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP
U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome
DNAnexus® Applauded by Frost & Sullivan for Supporting Better Clinical Decision-making and More Effective Therapies

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Limelon Advertising, Co.


  ©2005-2023 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today